Gedatolisib

About Celcuity

Celcuity is a clinical-stage biotech advancing a pipeline centered on its lead asset, gedatolisib, a potent, dual pan-PI3K/mTOR inhibitor. The company is targeting the difficult-to-blockade PAM pathway, with a current focus on hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer, where recent Phase 3 data in a PIK3CA wild-type cohort showed promising potential. Founded in 2012 and headquartered in Minneapolis, Celcuity is a public company transitioning from its diagnostic roots to a fully integrated oncology therapeutics developer, with its future heavily dependent on the successful development and regulatory approval of gedatolisib.

About Celcuity

Celcuity is a clinical-stage biotech advancing a pipeline centered on its lead asset, gedatolisib, a potent, dual pan-PI3K/mTOR inhibitor. The company is targeting the difficult-to-blockade PAM pathway, with a current focus on hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer, where recent Phase 3 data in a PIK3CA wild-type cohort showed promising potential. Founded in 2012 and headquartered in Minneapolis, Celcuity is a public company transitioning from its diagnostic roots to a fully integrated oncology therapeutics developer, with its future heavily dependent on the successful development and regulatory approval of gedatolisib.

Therapeutic Areas